May 7, 2025

Featuring perspectives from Prof Rebecca A Dent and Dr Nancy U Lin, including the following topics:

• Introduction: A New Paradigm for Triple-Positive Breast Cancer? (0:00)
• CDK4/6 Inhibitors for HR-Positive, HER2-Negative Breast Cancer (10:06)
• Oral Selective Estrogen Receptor Degraders for HR-Positive, HER2-Negative...

May 6, 2025

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Breast Cancer | Faculty Presentation 2: HER2-Positive Breast Cancer and Triple-Negative Breast Cancer (TNBC) — Nancy U Lin, MD

CME information and select...

May 6, 2025

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Breast Cancer | Faculty Presentation 1: HR-Positive Breast Cancer — Rebecca A Dent, MD, MSc

CME information and select publications

Apr 25, 2025

Featuring an interview with Dr Adam M Brufsky, including the following topics:

• Case: A woman in her early 50s with ER-positive, HER2-low de novo metastatic breast cancer (0:00)
• Case: A woman in her late 70s with ER-positive, HER2-low metastatic breast cancer after 5 years of an adjuvant aromatase inhibitor...

Apr 24, 2025

Featuring a slide presentation and related discussion from Dr Adam M Brufsky, including the following topics:

• Mechanism of action of and long-term data with CDK4/6 inhibitors in the management of metastatic breast cancer (mBC) (0:00)
• Comparing safety profiles of CDK4/6 inhibitors (9:49)
• Role of CDK4/6 inhibitors in...